- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
PET/CT detects colorectal cancer recurrences
PET/CT scans can confirm a suspected colorectal cancer recurrence at an early stage, helping significantly in treatment, according to a study presented at the ARRS annual meeting.
PET/CT scans can confirm a suspected colorectal cancer recurrence at an early stage, helping significantly in treatment, according to a study presented at the ARRS annual meeting.
Researchers at The Christie NHS Foundation Trust in Manchester, U.K., found 71 patients with suspected co-lorectal recurrence. Suspicion was based on CT and MR in 51 cases. The rest had a suspected recurrence based on a carcinoembryonic antigen test with unremarkable conventional imaging.
All 71 patients had a PET/CT scan to confirm or negate recurrence. The modality accurately confirmed a recurrence in 40 of 71 patients.
“This shows that PET/CT has a definite role in the management of patients with recurrent colorectal cancer in addition to conventional imaging and the CEA test,” said Dr. Rohit Kochhar, lead author of the study.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
